NCT02276443 - Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative | Biotech Hunter

Enrollment

798

Participants

Timeline

Start Date

November 9, 2015

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions

Invasive Breast CarcinomaStage I Breast Cancer AJCC v7Stage IA Breast Cancer AJCC v7Stage IB Breast Cancer AJCC v7Stage II Breast Cancer AJCC v6 and v7Stage IIA Breast Cancer AJCC v6 and v7Stage IIB Breast Cancer AJCC v6 and v7Stage III Breast Cancer AJCC v7Stage IIIA Breast Cancer AJCC v7Stage IIIB Breast Cancer AJCC v7Stage IIIC Breast Cancer AJCC v7Triple-Negative Breast Carcinoma

Interventions

DRUG

Chemotherapy

Receive standard chemotherapy

OTHER

Immunotherapy

Receive standard immunotherapy

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Lymph Node Biopsy

Undergo baseline lymph node evaluation

PROCEDURE

Ultrasonography

Undergo standard ultrasound

Trial Locations (5)

77030

M D Anderson Cancer Center, Houston

77079

MD Anderson West Houston, Houston

77384

MD Anderson in The Woodlands, Conroe

77478

MD Anderson in Sugar Land, Sugar Land

77573

MD Anderson League City, League City

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER